Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Numab Therapeutics

    Client Virtual Booth

    NUMAB THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Numab Therapeutics
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Numab Therapeutics AG Einsiedlerstrasse 34 CH-8820 Wädenswil Switzerland
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://numab.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Numab Therapeutics and Ono Pharmaceutical Announce an Option Agreement
    Numab Therapeutics and Ono Pharmaceutical Announce an Option Agreement

    https://www.globenewswire.com//news-release/2024/02/14/2828818/0/en/Numab-Therapeutics-and-Ono-Pharmaceutical-Announce-an-Option-and-Collaboration-Agreement-to-Develop-Multi-specific-Antibody-NM49-for-Treatment-of-Cancer.html

    GLOBENEWSWIRE
    14 Feb 2024
    Share Share
    Numab Therapeutics Announces First Patient Dosed in Phase 1 Study of NM26
    Numab Therapeutics Announces First Patient Dosed in Phase 1 Study of NM26

    https://www.businesswire.com/news/home/20231018978952/en

    BUSINESSWIRE
    19 Oct 2023
    Share Share
    Numab doses first subject in antibody therapeutic trial for AD
    Numab doses first subject in antibody therapeutic trial for AD

    https://www.clinicaltrialsarena.com/news/numab-antibody-therapeutic-ad/

    CLINICAL TRIALS ARENA
    15 May 2023
    Share Share
    Numab Therapeutics Announces First Subject Dosed in Ph1 Study of NM26 Program
    Numab Therapeutics Announces First Subject Dosed in Ph1 Study of NM26 Program

    https://www.businesswire.com/news/home/20230514005072/en

    BUSINESSWIRE
    15 May 2023
    Share Share
    Numab Therapeutics, Ono Pharmaceutical Enter Development and License Agreement
    Numab Therapeutics, Ono Pharmaceutical Enter Development and License Agreement

    https://www.businesswire.com/news/home/20220331005092/en

    BUSINESSWIRE
    30 Mar 2022
    Share Share
    Numab, 3SBio’s Sunshine Guojian Expand Partnership to Develop NM28
    Numab, 3SBio’s Sunshine Guojian Expand Partnership to Develop NM28

    https://www.businesswire.com/news/home/20211214005246/en

    BUSINESSWIRE
    14 Dec 2021
    Share Share
    Numab raises $111M to challenge Genmab, BioNTech for emerging PD-L1 opportunity
    Numab raises $111M to challenge Genmab, BioNTech for emerging PD-L1 opportunity

    https://www.fiercebiotech.com/biotech/numab-raises-111m-to-challenge-genmab-biontech-for-emerging-pd-l1-opportunity

    N. P. Taylor FIERCEBIOTECH
    21 May 2021
    Share Share
    Novo Holdings co-leads oversubscribed CHF 100 M Series C in Numab Therapeutics
    Novo Holdings co-leads oversubscribed CHF 100 M Series C in Numab Therapeutics

    https://www.prnewswire.com/news-releases/novo-holdings-co-leads-oversubscribed-chf-100-million-usd-110-m-series-c-in-numab-therapeutics-301295672.html

    PRNEWSWIRE
    20 May 2021
    Share Share
    Numab raises $111M to challenge Genmab, BioNTech for emerging PD-L1 opportunity
    Numab raises $111M to challenge Genmab, BioNTech for emerging PD-L1 opportunity

    https://www.fiercebiotech.com/biotech/numab-raises-111m-to-challenge-genmab-biontech-for-emerging-pd-l1-opportunity

    FIERCEBIOTECH
    20 May 2021
    Share Share
    Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
    Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

    https://www.businesswire.com/news/home/20210520005094/en/Numab-Therapeutics-Completes-Oversubscribed-CHF-100-Million-Series-C-Financing

    BUSINESSWIRE
    20 May 2021
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search